Browse SERPINF2

Summary
SymbolSERPINF2
Nameserpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 2
Aliases API; ALPHA-2-PI; A2AP; AAP; alpha-2-plasmin inhibitor; alpha-2-antiplasmin; PLI; serine (or cysteine) protei ......
Chromosomal Location17p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted.
Domain PF00079 Serpin (serine protease inhibitor)
Function

Serine protease inhibitor. The major targets of this inhibitor are plasmin and trypsin, but it also inactivates matriptase-3/TMPRSS7 and chymotrypsin.

> Gene Ontology
 
Biological Process GO:0001819 positive regulation of cytokine production
GO:0001990 regulation of systemic arterial blood pressure by hormone
GO:0002034 regulation of blood vessel size by renin-angiotensin
GO:0002526 acute inflammatory response
GO:0002576 platelet degranulation
GO:0003013 circulatory system process
GO:0003014 renal system process
GO:0003018 vascular process in circulatory system
GO:0003044 regulation of systemic arterial blood pressure mediated by a chemical signal
GO:0003071 renal system process involved in regulation of systemic arterial blood pressure
GO:0003072 renal control of peripheral vascular resistance involved in regulation of systemic arterial blood pressure
GO:0003073 regulation of systemic arterial blood pressure
GO:0003081 regulation of systemic arterial blood pressure by renin-angiotensin
GO:0006887 exocytosis
GO:0006953 acute-phase response
GO:0007015 actin filament organization
GO:0007254 JNK cascade
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0008015 blood circulation
GO:0008217 regulation of blood pressure
GO:0010466 negative regulation of peptidase activity
GO:0010712 regulation of collagen metabolic process
GO:0010714 positive regulation of collagen metabolic process
GO:0010755 regulation of plasminogen activation
GO:0010757 negative regulation of plasminogen activation
GO:0010951 negative regulation of endopeptidase activity
GO:0010955 negative regulation of protein processing
GO:0016485 protein processing
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0030038 contractile actin filament bundle assembly
GO:0030193 regulation of blood coagulation
GO:0030194 positive regulation of blood coagulation
GO:0030195 negative regulation of blood coagulation
GO:0030198 extracellular matrix organization
GO:0030199 collagen fibril organization
GO:0031032 actomyosin structure organization
GO:0031098 stress-activated protein kinase signaling cascade
GO:0031638 zymogen activation
GO:0031639 plasminogen activation
GO:0032102 negative regulation of response to external stimulus
GO:0032103 positive regulation of response to external stimulus
GO:0032231 regulation of actin filament bundle assembly
GO:0032233 positive regulation of actin filament bundle assembly
GO:0032872 regulation of stress-activated MAPK cascade
GO:0032874 positive regulation of stress-activated MAPK cascade
GO:0032956 regulation of actin cytoskeleton organization
GO:0032963 collagen metabolic process
GO:0032964 collagen biosynthetic process
GO:0032965 regulation of collagen biosynthetic process
GO:0032967 positive regulation of collagen biosynthetic process
GO:0032970 regulation of actin filament-based process
GO:0033002 muscle cell proliferation
GO:0035150 regulation of tube size
GO:0042730 fibrinolysis
GO:0043062 extracellular structure organization
GO:0043149 stress fiber assembly
GO:0043410 positive regulation of MAPK cascade
GO:0044089 positive regulation of cellular component biogenesis
GO:0044236 multicellular organism metabolic process
GO:0044246 regulation of multicellular organismal metabolic process
GO:0044253 positive regulation of multicellular organismal metabolic process
GO:0044259 multicellular organismal macromolecule metabolic process
GO:0044331 cell-cell adhesion mediated by cadherin
GO:0045055 regulated exocytosis
GO:0045785 positive regulation of cell adhesion
GO:0045861 negative regulation of proteolysis
GO:0046328 regulation of JNK cascade
GO:0046330 positive regulation of JNK cascade
GO:0048514 blood vessel morphogenesis
GO:0048659 smooth muscle cell proliferation
GO:0048660 regulation of smooth muscle cell proliferation
GO:0048661 positive regulation of smooth muscle cell proliferation
GO:0050817 coagulation
GO:0050818 regulation of coagulation
GO:0050819 negative regulation of coagulation
GO:0050820 positive regulation of coagulation
GO:0050878 regulation of body fluid levels
GO:0050880 regulation of blood vessel size
GO:0050886 endocrine process
GO:0051017 actin filament bundle assembly
GO:0051346 negative regulation of hydrolase activity
GO:0051403 stress-activated MAPK cascade
GO:0051492 regulation of stress fiber assembly
GO:0051493 regulation of cytoskeleton organization
GO:0051495 positive regulation of cytoskeleton organization
GO:0051496 positive regulation of stress fiber assembly
GO:0051604 protein maturation
GO:0051917 regulation of fibrinolysis
GO:0051918 negative regulation of fibrinolysis
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
GO:0061041 regulation of wound healing
GO:0061045 negative regulation of wound healing
GO:0061572 actin filament bundle organization
GO:0070302 regulation of stress-activated protein kinase signaling cascade
GO:0070304 positive regulation of stress-activated protein kinase signaling cascade
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
GO:0070374 positive regulation of ERK1 and ERK2 cascade
GO:0070613 regulation of protein processing
GO:0071604 transforming growth factor beta production
GO:0071634 regulation of transforming growth factor beta production
GO:0071636 positive regulation of transforming growth factor beta production
GO:0090066 regulation of anatomical structure size
GO:0090303 positive regulation of wound healing
GO:1900046 regulation of hemostasis
GO:1900047 negative regulation of hemostasis
GO:1900048 positive regulation of hemostasis
GO:1903034 regulation of response to wounding
GO:1903035 negative regulation of response to wounding
GO:1903036 positive regulation of response to wounding
GO:1903317 regulation of protein maturation
GO:1903318 negative regulation of protein maturation
GO:2000047 regulation of cell-cell adhesion mediated by cadherin
GO:2000049 positive regulation of cell-cell adhesion mediated by cadherin
Molecular Function GO:0002020 protease binding
GO:0004857 enzyme inhibitor activity
GO:0004866 endopeptidase inhibitor activity
GO:0004867 serine-type endopeptidase inhibitor activity
GO:0030414 peptidase inhibitor activity
GO:0061134 peptidase regulator activity
GO:0061135 endopeptidase regulator activity
Cellular Component GO:0005577 fibrinogen complex
GO:0030141 secretory granule
GO:0031091 platelet alpha granule
GO:0031093 platelet alpha granule lumen
GO:0031983 vesicle lumen
GO:0034774 secretory granule lumen
GO:0060205 cytoplasmic membrane-bounded vesicle lumen
GO:0072562 blood microparticle
GO:0099503 secretory vesicle
> KEGG and Reactome Pathway
 
KEGG hsa04610 Complement and coagulation cascades
Reactome R-HSA-75205: Dissolution of Fibrin Clot
R-HSA-109582: Hemostasis
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-114608: Platelet degranulation
R-HSA-76005: Response to elevated platelet cytosolic Ca2+
Summary
SymbolSERPINF2
Nameserpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 2
Aliases API; ALPHA-2-PI; A2AP; AAP; alpha-2-plasmin inhibitor; alpha-2-antiplasmin; PLI; serine (or cysteine) protei ......
Chromosomal Location17p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SERPINF2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolSERPINF2
Nameserpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 2
Aliases API; ALPHA-2-PI; A2AP; AAP; alpha-2-plasmin inhibitor; alpha-2-antiplasmin; PLI; serine (or cysteine) protei ......
Chromosomal Location17p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SERPINF2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSERPINF2
Nameserpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 2
Aliases API; ALPHA-2-PI; A2AP; AAP; alpha-2-plasmin inhibitor; alpha-2-antiplasmin; PLI; serine (or cysteine) protei ......
Chromosomal Location17p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SERPINF2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.6330.298
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.2350.836
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)871.2780.132
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.220.768
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.8190.59
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.5360.431
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1150.864
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.5640.556
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.6010.584
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3740.858
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.4210.898
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.6010.0029
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SERPINF2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 512200200.294
Summary
SymbolSERPINF2
Nameserpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 2
Aliases API; ALPHA-2-PI; A2AP; AAP; alpha-2-plasmin inhibitor; alpha-2-antiplasmin; PLI; serine (or cysteine) protei ......
Chromosomal Location17p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SERPINF2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSERPINF2
Nameserpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 2
Aliases API; ALPHA-2-PI; A2AP; AAP; alpha-2-plasmin inhibitor; alpha-2-antiplasmin; PLI; serine (or cysteine) protei ......
Chromosomal Location17p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SERPINF2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SERPINF2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSERPINF2
Nameserpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 2
Aliases API; ALPHA-2-PI; A2AP; AAP; alpha-2-plasmin inhibitor; alpha-2-antiplasmin; PLI; serine (or cysteine) protei ......
Chromosomal Location17p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SERPINF2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSERPINF2
Nameserpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 2
Aliases API; ALPHA-2-PI; A2AP; AAP; alpha-2-plasmin inhibitor; alpha-2-antiplasmin; PLI; serine (or cysteine) protei ......
Chromosomal Location17p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SERPINF2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSERPINF2
Nameserpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 2
Aliases API; ALPHA-2-PI; A2AP; AAP; alpha-2-plasmin inhibitor; alpha-2-antiplasmin; PLI; serine (or cysteine) protei ......
Chromosomal Location17p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SERPINF2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSERPINF2
Nameserpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 2
Aliases API; ALPHA-2-PI; A2AP; AAP; alpha-2-plasmin inhibitor; alpha-2-antiplasmin; PLI; serine (or cysteine) protei ......
Chromosomal Location17p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SERPINF2 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting SERPINF2.
ID Name Drug Type Targets #Targets
DB08888OcriplasminBiotechA2M, FN1, SERPINF23
DB09130CopperSmall MoleculeA1BG, ACTG1, ACTN1, ACY1, AFM, AGT, AHCY, AHSG, AKR1A1, ANXA4, ANX ......141